8 weeks 
8 weeks 
2. X 
1.0 Introduction 
1.1 Background and Rationale 
1.1.1 Ovarian Cancer 
1.1.2 Chemistry and Pharmacology of DOXIL/CAELYX 
1.1.3 Rationale for the Use of DOXIL/CAELYX 
1.1.4 Rationale for the Use of Topotecan 
1.2 Objective 
1.3 Study Design 
2.0 Patient Enrollment 
2.1 Inclusion Criteria 
2.1.2 All patients must have measurable disease or measurable and 
2.1.3 Recurrence of disease or disease progression indicative of failure of 
2.1.11 Disease free from prior malignancies for 5 years with the exception 
2.2 Exclusion Criteria 
2.2.8 Prior chemotherapy within 28 days of first dose of study drug (or 42 
2.3 Patient Registration 
2.4 Randomization 
3.0 Study Activities 
3.1.1 Signed informed consent 
3.1.2 Medical History 
3.1.5 MUGA scan to evaluate left ventricular ejection fraction (within 
3.1.6 12 lead electrocardiogram (within 7 days prior to first dose of study 
3.2 Day 1 (DOXIL/CAELYX) or Days 1 5 (Topotecan) 
3.2.1 Health related Quality of Life Questionnaire must be completed by the 
3.3 Weekly 
3.4 Every Cycle 
3.4.1 Health related Quality of Life Questionnaire must be completed by the 
3.5 Every 2 Cycles 
3.5.1 For patients randomized to receive DOXIL/CAELYX: After patients 
3.6 Every 8 Weeks 
3.6.1 Appropriate radiologic assessments of response using same 
3.7 End of Treatment (4 weeks after the last dose) 
3.7.1 Health related Quality of Life Questionnaire must be completed by the 
3.8 Follow Up (every 3 months after the last dose) 
3.9 Study Completion 
4.0 Administration of Study Drug 
4.1 Investigational Drug Supply 
4.2.1 Topotecan 
4.2.2 DOXIL/CAELYX 
4.3 Precautions 
4.3.1 Topotecan 
4.3.1.1 Hematologic 
4.3.1.2 Renal Function Impairment 
4.3.2 DOXIL/CAELYX 
4.3.2.1 Palmar Plantar Erythrodysesthesia 
4.3.2.2 Hematologic Toxicities 
4.3.2.3 Bilirubin 
4.3.2.4 Stomatitis 
4.4 Criteria for Temporary Suspension or Premature Discontinuation of 
4.4.3 Patients requiring radiation therapy (palliative or primary) should be 
5.0 Concomitant Medications 
5.4  The prophylactic use of cytokines is discouraged in conjunction with the first 
5.1 All concomitant medications will be recorded from dosing on day 1 until the 
6.0 Adverse Experiences 
6.1 Definitions 
6.2 Reporting Adverse Events 
6.3 Serious Adverse Events 
7.0 Health related Quality of Life 
7.1 Background and Objectives 
7.2 Schedule of HQL Evaluations 
8.0 Study Analysis 
8.1 Definitions of Disease 
8.1.1 Measurable Disease: Bidimensionally measurable lesions with clearly 
8.2 Definitions of Response 
8.2.1 Complete Response (CR): Complete disappearance of all measurable 
8.3 Efficacy Assessments 
8.3.1 Primary efficacy parameters 
8.3.2 Secondary Efficacy Parameters 
8.3.2.1 Response Rate: The definitions of response are described in 
8.3.2.2 Time to Response 
8.3.2.3 Duration of Response 
8.3.2.4 Health related Quality of Life 
8.3.2.5 Survival 
8.3.2.6 Quality adjusted Survival 
8.4 Stratification 
8.5 Patient Populations 
8.5.1 Intent to Treat Population (ITT) 
8.6 Data Analysis And Statistical Consideration 
8.5.2 Evaluable Population 
8.6.1 Data Analysis 
8.6.3 Response Analysis 
8.6.4 Duration of Response 
8.6.5 Analysis of HQL Data 
8.6.6 Analysis of Q TWiST 
8.6.7 Statistical Power and Sample Size Considerations 
8.7 Interim Analysis 
8.8 Additional 
8.9 Safety Analyses 
9.0 Study Administration and Investigator Obligations 
9.1 Institutional Review Board 
9.2 Informed Consent 
9.3 Drug Accountability 
9.4 Record Retention 
9.5 Case Report Forms 
9.6 Monitoring the Study 
9.7 Termination of Study 
9.7.4 The incidence and/or severity of adverse drug experiences in this or 
9.8 Study Amendments 
9.9 Publication Statement 
10.0 References 
11. Christian MC and EL Trimble: Salvage Chemotherapy for Epithelial Ovarian 
14. sarcoma patients treated with pegylated liposomal doxorubicin (DOXIL ) as 
1993. (Supplement A) 
75.0 normal 
10.0 normal 
100.4 F 
3. Do you have any trouble taking a short walk outside of the 
28. Have you had difficulty in concentrating on 
33. Did you have pain or discomfort with bowel 
43. Did soreness in your mouth or throat interfere with 
44. Have you had a problem with changes in sensation 
47. Did you have blistering or cracking of the skin of 
49. Did you have a decrease in your interest in sexual 
2. The design and performance of each experimental procedure involving human 
3. Biomedical research involving human subjects should be conducted only by 
4. Biomedical research involving human subjects cannot legitimately be carried out 
5. Every biomedical research project involving human subjects should be preceded by 
6. The right of the research subject to safeguard his or her integrity must always be 
7. Physicians should abstain from engaging in research projects involving human 
10. When obtaining informed consent for the research project the physician should be 
12. The research protocol should always contain a statement of the ethical considerations 
2. Location: 
5. Location: 
2. Location: 
7.3 Analysis of HQL Data 
8.3.1.2 Response Rate: The definitions of response are described in 
8.3.2.1 Response Rate: The definitions of response are described in 
10. Location: 
11. Location: 
12. Location: 
8.3.2.6 Quality adjusted Survival 
13. Location: 
14. Location: 
8.6.5 Analysis of HQL Data 
8.6.6 Quality adjusted survival will be calculated using the Quality adjusted 
15. Location: 
16. Location: 
8.8 Additional Analyses 
